Agendia plans to raise €75m by going public
This article was originally published in Clinica
Executive Summary
Dutch firm Agendia today launched its initial public offering on the NYSE Euronext stock exchange in Amsterdam, aiming to raise up to €75m ($109.6m). The cancer molecular diagnostics specialist plans to use the funds to expand its sales and marketing activities in the US, where it currently markets four breast cancer tests in its Symphony product line.